Oxford Biomedica strikes new AAV agreements with US firms

Gene and cell therapy company Oxford Biomedica has struck agreements with three US biotechnology companies, bringing the firm's total number of new adeno-associated virus customers in 2022 to four.

Oxford Biomedica said on Wednesday that its Oxford Biomedica Solutions unit had inked the deals with the undisclosed firms, with the subsidiary set to provide its full platform to support its new partners' pre-clinical gene therapy programmes.

The London-listed firm did not provide any financial terms related to the deals.

Chairman Dr Roch Doliveux said: "Securing four new AAV customers in 2022 exceeds our original stated target of two new customers by the end of 2022. We are making considerable progress towards becoming a global viral vector leader across all key vector types, with this momentum in Oxford Biomedica Solutions adding to the strength and depth of our UK-based operations.

"AAV is a significant, high-growth market, and the cadence of new business wins further reinforces our confidence in the potential of our AAV platform, which has already demonstrated high-titre product quality and a full breadth of capabilities. We enter 2023 with great confidence and look forward to continuing to build our position as a world-class, innovation-led CDMO delivering life-changing and life-altering therapies to patients ."

As of 0845 GMT, Oxford Biomedica shares were down 0.28% at 381.94p.

Reporting by Iain Gilbert at Sharecast.com